复星医药王兴利:引领创新下半场,走出一条MNC之路

医药魔方
Oct 17

在不久前结束的第五届中国医药决策者峰会上,“医药魔方·十年荣耀”榜单揭晓,复星医药荣获“行业引领制药企业”大奖。在榜单揭晓前,复星医药公布了2025年半年报,创新药品收入稳健增长,超43亿元,同比增长14.26%;此外,2025年上半年,复星医药实现海外收入54.78亿元,占营收比重为28.07%。创新药品收入占比和海外市场收入占比是衡量企业创新驱动和国际化战略的重要指标,在这两点上,复星医药都在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10